AP2015008439A0 - Substituted phthalazin-1(2H)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 - Google Patents
Substituted phthalazin-1(2H)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1Info
- Publication number
- AP2015008439A0 AP2015008439A0 AP2015008439A AP2015008439A AP2015008439A0 AP 2015008439 A0 AP2015008439 A0 AP 2015008439A0 AP 2015008439 A AP2015008439 A AP 2015008439A AP 2015008439 A AP2015008439 A AP 2015008439A AP 2015008439 A0 AP2015008439 A0 AP 2015008439A0
- Authority
- AP
- ARIPO
- Prior art keywords
- adp
- ribose
- polymerase
- poly
- derivatives
- Prior art date
Links
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 title 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3742MU2012 | 2012-12-31 | ||
| PCT/IN2013/000794 WO2014102817A1 (en) | 2012-12-31 | 2013-12-23 | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2015008439A0 true AP2015008439A0 (en) | 2015-05-31 |
Family
ID=54198806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008439A AP2015008439A0 (en) | 2012-12-31 | 2013-12-23 | Substituted phthalazin-1(2H)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9598418B2 (pl) |
| EP (1) | EP2938598B1 (pl) |
| JP (1) | JP5930452B2 (pl) |
| KR (1) | KR101652654B1 (pl) |
| CN (1) | CN104918917A (pl) |
| AP (1) | AP2015008439A0 (pl) |
| AR (1) | AR094299A1 (pl) |
| AU (1) | AU2013368842B2 (pl) |
| BR (1) | BR112015012425A2 (pl) |
| CA (1) | CA2890309A1 (pl) |
| CL (1) | CL2015001655A1 (pl) |
| CO (1) | CO7400872A2 (pl) |
| DK (1) | DK2938598T3 (pl) |
| EA (1) | EA201591239A1 (pl) |
| ES (1) | ES2614885T3 (pl) |
| GE (1) | GEP201706691B (pl) |
| HR (1) | HRP20170219T1 (pl) |
| HU (1) | HUE030613T2 (pl) |
| IL (1) | IL238714A0 (pl) |
| MA (1) | MA38080A1 (pl) |
| MX (1) | MX2015006780A (pl) |
| NZ (1) | NZ708255A (pl) |
| PH (1) | PH12015501199B1 (pl) |
| PL (1) | PL2938598T3 (pl) |
| PT (1) | PT2938598T (pl) |
| SG (1) | SG11201503670YA (pl) |
| TW (1) | TWI553005B (pl) |
| WO (1) | WO2014102817A1 (pl) |
| ZA (1) | ZA201503218B (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| CN105764905B (zh) | 2013-11-26 | 2019-06-07 | 豪夫迈·罗氏有限公司 | 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基 |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| RU2018112230A (ru) * | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| KR20180054830A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서의 이환형 화합물 |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| CR20180057A (es) * | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| CN107428762B (zh) * | 2015-10-30 | 2020-03-10 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| CN107207504B (zh) * | 2015-12-16 | 2020-03-10 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| HUE066216T2 (hu) | 2016-06-24 | 2024-07-28 | Univ California | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| CN109251204A (zh) * | 2017-07-13 | 2019-01-22 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN108164468B (zh) * | 2018-02-09 | 2021-02-02 | 上海卫岑医药科技有限公司 | 一种parp抑制剂、其药物组合物、制备方法及应用 |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| WO2021225407A1 (ko) * | 2020-05-08 | 2021-11-11 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| US20240208912A1 (en) * | 2021-03-11 | 2024-06-27 | Mirati Therapeutics, Inc. | MTA-Cooperative PRMT5 Inhibitors |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20240317762A1 (en) * | 2021-07-16 | 2024-09-26 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
| EP4493555A4 (en) * | 2022-03-15 | 2026-03-25 | Beone Medicines I Gmbh | 4-(AMINOMETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)ISOQUINOLIN-1(2H)-ONE DERIVATIVES USED AS PRMT5 INHIBITORS COOPERATE WITH MTA |
| CN119365468A (zh) * | 2022-08-31 | 2025-01-24 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
| CN116874496B (zh) * | 2023-07-10 | 2025-07-25 | 东南大学 | 三环类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| PL223343B1 (pl) | 2000-10-30 | 2016-10-31 | Kudos Pharm Ltd | Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| BRPI0418351A (pt) | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| CA2577191A1 (en) | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用 |
| DE602006020335D1 (de) | 2005-11-25 | 2011-04-07 | Pharma Mar Sa | Verwendung von parp-1-hemmern |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| DK2120579T3 (da) * | 2006-12-28 | 2014-02-03 | Abbvie Inc | Inhibitorer af poly(ADP-ripose)polymerase |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| CN101743003A (zh) | 2007-05-25 | 2010-06-16 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的chk和parp抑制剂的组合 |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| ES2524787T3 (es) * | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| ES2598178T5 (es) | 2008-10-07 | 2023-12-26 | Kudos Pharm Ltd | Formulación farmacéutica 514 |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| KR101528688B1 (ko) * | 2010-12-02 | 2015-06-12 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| EP2714703B1 (en) | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| RU2606635C2 (ru) | 2011-07-13 | 2017-01-10 | Сантен Фармасьютикал Ко., Лтд. | Новое соединение, проявляющее ингибиторную активность в отношении parp |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| MX2014008071A (es) | 2011-12-31 | 2015-07-06 | Beigene Ltd | Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas. |
| CN103242273B (zh) | 2012-02-09 | 2015-06-03 | 中国科学院上海药物研究所 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
| KR20140121477A (ko) | 2012-02-09 | 2014-10-15 | 메르크 파텐트 게엠베하 | Ｔａｎｋ 및 ｐａｒｐ 저해체로서의 테트라히드로-퀴나졸리논 |
-
2013
- 2013-12-23 PL PL13828996T patent/PL2938598T3/pl unknown
- 2013-12-23 HU HUE13828996A patent/HUE030613T2/en unknown
- 2013-12-23 JP JP2015550210A patent/JP5930452B2/ja not_active Expired - Fee Related
- 2013-12-23 AP AP2015008439A patent/AP2015008439A0/xx unknown
- 2013-12-23 US US14/647,088 patent/US9598418B2/en not_active Expired - Fee Related
- 2013-12-23 KR KR1020157017355A patent/KR101652654B1/ko not_active Expired - Fee Related
- 2013-12-23 GE GEAP201313901A patent/GEP201706691B/en unknown
- 2013-12-23 AU AU2013368842A patent/AU2013368842B2/en not_active Ceased
- 2013-12-23 SG SG11201503670YA patent/SG11201503670YA/en unknown
- 2013-12-23 WO PCT/IN2013/000794 patent/WO2014102817A1/en not_active Ceased
- 2013-12-23 MX MX2015006780A patent/MX2015006780A/es unknown
- 2013-12-23 NZ NZ708255A patent/NZ708255A/en not_active IP Right Cessation
- 2013-12-23 CN CN201380069025.0A patent/CN104918917A/zh active Pending
- 2013-12-23 EA EA201591239A patent/EA201591239A1/ru unknown
- 2013-12-23 ES ES13828996.2T patent/ES2614885T3/es active Active
- 2013-12-23 EP EP13828996.2A patent/EP2938598B1/en not_active Not-in-force
- 2013-12-23 PT PT138289962T patent/PT2938598T/pt unknown
- 2013-12-23 MA MA38080A patent/MA38080A1/fr unknown
- 2013-12-23 CA CA2890309A patent/CA2890309A1/en not_active Abandoned
- 2013-12-23 BR BR112015012425A patent/BR112015012425A2/pt not_active IP Right Cessation
- 2013-12-23 DK DK13828996.2T patent/DK2938598T3/en active
- 2013-12-26 TW TW102148473A patent/TWI553005B/zh not_active IP Right Cessation
- 2013-12-27 AR ARP130105054A patent/AR094299A1/es unknown
-
2015
- 2015-05-08 ZA ZA2015/03218A patent/ZA201503218B/en unknown
- 2015-05-10 IL IL238714A patent/IL238714A0/en not_active IP Right Cessation
- 2015-05-28 PH PH12015501199A patent/PH12015501199B1/en unknown
- 2015-06-03 CO CO15127891A patent/CO7400872A2/es unknown
- 2015-06-12 CL CL2015001655A patent/CL2015001655A1/es unknown
-
2017
- 2017-02-09 HR HRP20170219TT patent/HRP20170219T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170219T1 (hr) | Supstituirani derivati ftalazin-1(2h)-ona kao selektivni inhibitori poli(adp-riboza)polimeraze-1 | |
| ZA201406078B (en) | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors | |
| SG11201506099XA (en) | Macrocyclic pyridazinone derivatives | |
| SI2857404T1 (sl) | Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji | |
| IL239193A0 (en) | New Benzimidazole Derivatives as Kinase Inhibitors | |
| IL238553A0 (en) | Modified indole-5-ol derivatives, preparations containing them and methods for their preparation | |
| IL239562A0 (en) | Derivatives of 1-(converted-benzoyl)-5-fluoro-4-imino-3-methyl-4,3-dihydropyrimidine-2(1h)-one | |
| ZA201303614B (en) | Quinazolin-4(3h)-one derivatives used as p13 kinase inhibitors | |
| ZA201309187B (en) | Pyridin-2(1h)-one derivatives as jak inhibitors | |
| IL239561B (en) | Derivatives of n-(converted)-5-fluoro-4-imino-3-methyl-2-oxo-4,3-dihydropyrimidine-1(2h)-carboxylate | |
| SG11201500732TA (en) | (aza-)isoquinolinone derivatives | |
| ZA201407828B (en) | Bicyclic pyrazinone derivatives | |
| PT2912032T (pt) | Derivados de 4-carboxamido-isoindolinona como inibidores seletivos de parp-1 | |
| GB2521802B (en) | Reissue of crypographic credentials | |
| HUE037285T2 (hu) | Dihidropirimidin származékok kristályos formái |